GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Earnings per Share (Diluted)

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Earnings per Share (Diluted) : HK$-1.59 (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Earnings per Share (Diluted)?

Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was HK$0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.59.

Sichuan Kelun-Biotech Biopharmaceutical Co's EPS (Basic) for the three months ended in Dec. 2023 was HK$0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.59.

Sichuan Kelun-Biotech Biopharmaceutical Co's EPS without NRI for the three months ended in Dec. 2023 was HK$0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.96.


Sichuan Kelun-Biotech Biopharmaceutical Co Earnings per Share (Diluted) Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Earnings per Share (Diluted) Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Earnings per Share (Diluted)
-5.05 -2.84 -3.11

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial -1.47 -0.26 -1.17 -0.16 -

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings per Share (Diluted)

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun-Biotech Biopharmaceutical Co's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's PE Ratio falls into.



Sichuan Kelun-Biotech Biopharmaceutical Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-627.976-0)/183.629
=-3.42

Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0-0)/183.629
=0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sichuan Kelun-Biotech Biopharmaceutical Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines